deferiprone has been researched along with Dysmyelopoietic Syndromes in 22 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients)." | 7.79 | A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. ( Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J, 2013) |
| "Five, repeatedly transfused, patients with refractory anemia (RA) or RA with ringed sideroblast (RARS) subtypes of myelodysplastic syndrome (MDS), with serum ferritin (SF) levels of > 2,000 microg/L, and one female with Hb E [beta26(B8)Glu --> Lys]/beta0-thalassemia (thal) with an SF level of 1,760 microg/ L, were treated with deferiprone (L1) at the dose of 4-6 g per day for at least 26 months." | 5.12 | Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. ( Cermák, J, 2006) |
| "One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients)." | 3.79 | A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. ( Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J, 2013) |
| " Incidence of adverse effects was comparable to that in thalassemic patients." | 2.76 | Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. ( Cermak, J; Hochova, I; Jonasova, A; Neuwirtova, R; Siskova, M; Vondrakova, J; Walterova, L, 2011) |
| "Deferiprone was clearly not effective in three patients (two with myelofibrosis, one with myelodysplasia)." | 2.68 | Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. ( Goudsmit, R; Kersten, MJ; Lameijer, W; Lange, R; Roozendaal, KJ; Smeets, ME; Vreugdenhil, G, 1996) |
| "Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
| "Deferasirox is an oral iron-chelating agent with favorable pharmacokinetics, including a long half-life allowing continuous 24-hour chelation with once-daily dosing." | 2.44 | Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. ( Goldberg, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, SA | 1 |
| Leitch, HA | 1 |
| Ghosh, K | 2 |
| Cermak, J | 3 |
| Jonasova, A | 2 |
| Vondrakova, J | 2 |
| Cervinek, L | 1 |
| Belohlavkova, P | 1 |
| Neuwirtova, R | 2 |
| de Witte, T | 1 |
| Jang, JH | 1 |
| Lee, JH | 1 |
| Yoon, SS | 1 |
| Jo, DY | 1 |
| Kim, HJ | 1 |
| Chung, J | 1 |
| Lee, JW | 1 |
| Merkel, DG | 1 |
| Nagler, A | 1 |
| Malcovati, L | 1 |
| Fausel, CA | 1 |
| Walterova, L | 1 |
| Hochova, I | 1 |
| Siskova, M | 1 |
| Shah, J | 1 |
| Kurtin, SE | 1 |
| Arnold, L | 1 |
| Lindroos-Kolqvist, P | 1 |
| Tinsley, S | 1 |
| Ruivard, M | 1 |
| Greenberg, PL | 1 |
| Barton, JC | 1 |
| Ghoti, H | 1 |
| Amer, J | 1 |
| Winder, A | 1 |
| Rachmilewitz, E | 1 |
| Fibach, E | 1 |
| Goldberg, SL | 1 |
| Kontoghiorghes, GJ | 3 |
| Bartlett, AN | 3 |
| Sheppard, L | 2 |
| Barr, J | 2 |
| Nortey, P | 2 |
| Kersten, MJ | 1 |
| Lange, R | 1 |
| Smeets, ME | 1 |
| Vreugdenhil, G | 1 |
| Roozendaal, KJ | 1 |
| Lameijer, W | 1 |
| Goudsmit, R | 1 |
| Klinz, C | 1 |
| Rose, C | 1 |
| Cambier, N | 1 |
| Mahieu, M | 1 |
| Ernst, O | 1 |
| Fenaux, P | 1 |
| Hoffbrand, AV | 2 |
| Goddard, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
| Kinetics of the Plasmatic Concentration of L-Ascorbic Acid in Patient With Myelodysplastic Syndromes and Control Subjects[NCT02809222] | 138 participants (Actual) | Interventional | 2016-10-25 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for deferiprone and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Def | 2014 |
Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Topics: beta-Thalassemia; Deferiprone; Disease Progression; DNA Methylation; Erythrocyte Transfusion; Erythr | 2009 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Ir | 2013 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythroc | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron C | 2007 |
[Iron overload and myelodysplastic syndromes].
Topics: Administration, Oral; Aged; Biopsy; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte Transf | 2001 |
6 trials available for deferiprone and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Drug Therapy, Combination; Drug-Relate | 2011 |
Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.
Topics: Administration, Oral; Anemia, Refractory; Deferiprone; Drug Administration Schedule; Drug Therapy, C | 2006 |
Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Topics: Adult; Aged; Ascorbic Acid; beta-Thalassemia; Deferiprone; Feces; Female; Ferritins; Humans; Iron; I | 1995 |
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Female; Ferritins; Hemosiderosis; Huma | 1996 |
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
Topics: Anemia; Blood Transfusion; Deferiprone; Ferritins; Half-Life; Humans; Iron; Iron Chelating Agents; M | 1990 |
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.
Topics: Adolescent; Adult; Aged; Anemia; Blood Transfusion; Deferiprone; Female; Humans; Iron; Iron Chelatin | 1990 |
8 other studies available for deferiprone and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine | 2018 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferr | 2013 |
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Mye | 2013 |
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Age | 2013 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Hum | 2010 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
[Marked hemosiderosis in myelodysplastic syndrome].
Topics: Aged; Deferiprone; Diabetes Mellitus, Type 2; Erythrocyte Transfusion; Heart Failure; Hemosiderosis; | 1999 |